Change - Announcement of Appointment::Appointment of Non-Independent Non-Executive Director - Mathias Lars Ove Lidgren

Issuer & Securities

Issuer/ Manager
REX INTERNATIONAL HOLDING LIMITED
Securities
REX INTERNATIONAL HOLDING LTD - SG2G04994999 - 5WH
Stapled Security
No

Announcement Details

Announcement Title
Change - Announcement of Appointment
Date &Time of Broadcast
04-May-2022 17:32:20
Status
New
Announcement Sub Title
Appointment of Non-Independent Non-Executive Director - Mathias Lars Ove Lidgren
Announcement Reference
SG220504OTHRSL6M
Submitted By (Co./ Ind. Name)
Dan Brostrom
Designation
Executive Director and Chairman
Description (Please provide a detailed description of the event in the box below)
Appointment of Dr Mathias Lars Ove Lidgren ("Dr Mathias Lidgren") as Non-Independent Non-Executive Director of the Company

Additional Details

Date Of Appointment
04/05/2022
Name Of Person
Mathias Lars Ove Lidgren
Age
40
Country Of Principal Residence
Sweden
The Board's comments on this appointment (including rationale, selection criteria, and the search and nomination process)
Dr Mathias Lidgren was nominated by Limea Ltd., the controlling shareholder of the Company. The Nominating Committee ("NC") has reviewed Dr Mathias Lidgren's background, professional qualifications, expertise and working experience to be complementary to the skills diversity of the Board, and recommended his appointment to the Board for approval. As part of the Company's progressive renewal of the Board, the Board of Directors has accepted the NC's recommendation and approved the appointment of Dr Mathias Lidgren as a Non-Executive Non-Independent Director of the Company.
Whether appointment is executive, and if so, the area of responsibility
Non-Executive
Job Title (e.g. Lead ID, AC Chairman, AC Member etc.)
Non-Independent Non-Executive Director and Member of Nominating Committee
Professional qualifications
a) PhD in Health Economics - Karolinska Institutet (Sweden)
b) Master of Arts in Genetics - University of Cambridge (United Kingdom)
c) Bachelor of Science in Business Administration (BSBA) - International University of Monaco
d) Medical degree (MB Bchir) - University of Cambridge (United Kingdom)
e) Recognition of medical degree - Commission des professions medicales (Switzerland)
f) License to practice medicine in the canton of Geneva, Switzerland - Le departement de lemploi, des affiaires sociales et de la sante (Switzerland)
g) Recognition of medical degree and license to practice medicine in Sweden and Board-certified specialist in clinical genetics - Socialstyrelsen (Sweden)
Any relationship (including immediate family relationships) with any existing director, existing executive officer, the issuer and/ or substantial shareholder of the listed issuer or any of its principal subsidiaries
Yes. Dr Mathias Lidgren is the son of Mr Hans Lidgren (controlling shareholder), nephew of Dr Karl Lidgren (Executive Director and controlling shareholder), and first cousin of Mr Mans Lidgren (Chief Executive Officer) and brother of Ms Lina Berntsen (Chief Technology Officer).

Mr Hans Lidgren and Dr Karl Lidgren are deemed interested in 34.71% of the Company's shares held by Limea Ltd., in which each of Mr Hans Lidgren and Cresta Group Ltd ("Cresta") has a 50% shareholding interest in respectively. Cresta is in turn wholly-owned by Dr Karl Lidgren.
Conflict of interests (including any competing business)
No
Working experience and occupation(s) during the past 10 years
2013 - 2015
Medical Doctor, National Health Service, NHS, United Kingdom

2015 - 2017
Medical Doctor, Hopitaux Universitaires de Geneeve, Geneva, Switzerland

2017 - 2018
Medical Doctor, Sahlgrenska University Hospital, Gothenburg, Sweden

2019 - Present
Medical Doctor, Skane University Hospitals, Lund, Sweden

2021 - Present
Postdoctoral Researcher, Division of Molecular Medicine and Gene Therapy, Department of Laboratory Medicine, Lund University, Lund, Sweden
Undertaking submitted to the listed issuer in the form of Appendix 7.7 (Listing Rule 704(7)) Or Appendix 7H (Catalist Rule 704(6))
Yes
Shareholding interest in the listed issuer and its subsidiaries?
Yes
Shareholding Details
Direct interest: 7,000,000 ordinary shares (representing 0.54% interest in Rex International Holding Limited) held through Citibank N.A. Singapore
# These fields are not applicable for announcements of appointments pursuant to Listing Rule 704 (9) or Catalist Rule 704 (8).
Past (for the last 5 years)
Directorships
Nil

Other Principal Commitments
- Medical Doctor, Sahlgrenska University Hospital, Gothenburg, Sweden
Present
Directorships
- Propatria AB
- Rotationsplast i Munka-Ljungby AB
- Caithness Fastighets AB
- Forvaltningsaktiebolaget Maple
- Trolleholms Slott AB
- Captiosus AB
- Strominnate Therapeutics AB

Other Principal Commitments
- Medical Doctor (Skane University Hospitals, Lund, Sweden)
- Postdoctoral Researcher (Division of Molecular Medicine and Gene Therapy, Department of Laboratory Medicine, Lund University, Lund, Sweden)
(a) Whether at any time during the last 10 years, an application or a petition under any bankruptcy law of any jurisdiction was filed against him or against a partnership of which he was a partner at the time when he was a partner or at any time within 2 years from the date he ceased to be a partner?
No
(b) Whether at any time during the last 10 years, an application or a petition under any law of any jurisdiction was filed against an entity (not being a partnership) of which he was a director or an equivalent person or a key executive, at the time when he was a director or an equivalent person or a key executive of that entity or at any time within 2 years from the date he ceased to be a director or an equivalent person or a key executive of that entity, for the winding up or dissolution of that entity or, where that entity is the trustee of a business trust, that business trust, on the ground of insolvency?
No
(c) Whether there is any unsatisfied judgment against him?
No
(d) Whether he has ever been convicted of any offence, in Singapore or elsewhere, involving fraud or dishonesty which is punishable with imprisonment, or has been the subject of any criminal proceedings (including any pending criminal proceedings of which he is aware) for such purpose?
No
(e) Whether he has ever been convicted of any offence, in Singapore or elsewhere, involving a breach of any law or regulatory requirement that relates to the securities or futures industry in Singapore or elsewhere, or has been the subject of any criminal proceedings (including any pending criminal proceedings of which he is aware) for such breach?
No
(f) Whether at any time during the last 10 years, judgment has been entered against him in any civil proceedings in Singapore or elsewhere involving a breach of any law or regulatory requirement that relates to the securities or futures industry in Singapore or elsewhere, or a finding of fraud, misrepresentation or dishonesty on his part, or he has been the subject of any civil proceedings (including any pending civil proceedings of which he is aware) involving an allegation of fraud, misrepresentation or dishonesty on his part?
No
(g) Whether he has ever been convicted in Singapore or elsewhere of any offence in connection with the formation or management of any entity or business trust?
No
(h) Whether he has ever been disqualified from acting as a director or an equivalent person of any entity (including the trustee of a business trust), or from taking part directly or indirectly in the management of any entity or business trust?
No
(i) Whether he has ever been the subject of any order, judgment or ruling of any court, tribunal or governmental body, permanently or temporarily enjoining him from engaging in any type of business practice or activity?
No
(j) Whether he has ever, to his knowledge, been concerned with the management or conduct, in Singapore or elsewhere, of the affairs of :-
(i) any corporation which has been investigated for a breach of any law or regulatory requirement governing corporations in Singapore or elsewhere; or
No
(ii) any entity (not being a corporation) which has been investigated for a breach of any law or regulatory requirement governing such entities in Singapore or elsewhere; or
No
(iii) any business trust which has been investigated for a breach of any law or regulatory requirement governing business trusts in Singapore or elsewhere; or
No
(iv) any entity or business trust which has been investigated for a breach of any law or regulatory requirement that relates to the securities or futures industry in Singapore or elsewhere, in connection with any matter occurring or arising during that period when he was so concerned with the entity or business trust?
No
(k) Whether he has been the subject of any current or past investigation or disciplinary proceedings, or has been reprimanded or issued any warning, by the Monetary Authority of Singapore or any other regulatory authority, exchange, professional body or government agency, whether in Singapore or elsewhere?
No
Any prior experience as a director of an issuer listed on the Exchange?
No
If no, please state if the director has attended or will be attending training on the roles and responsibilities of a director of a listed issuer as prescribed by the Exchange
The Company will make arrangements for Dr Mathias Lidgren to attend the training in the roles and responsibilities of a director of a listed issuer as prescribed by the Exchange within one year from the date of his appointment to the board.
Please provide details of relevant experience and the nominating committee's reasons for not requiring the director to undergo training as prescribed by the Exchange (if applicable)
Not Applicable